PBYI — Puma Biotechnology, Inc. stock price, charts and financials

QT83Puma Biotechnology, Inc.

Puma Biotechnology, Inc. (NASDAQ: PBYI) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
9.60
+0.08+0.84%
OverviewShort InterestFilings
PBYIQT83Puma Biotechnology, Inc.·NASDAQ
9.60+0.84%
News
Up 0.8% — PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NKTR-1.84%$67.10RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57MESO+1.75%$15.13AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83
Snapshot
Index-P/E18.46EPS (ttm)0.52Insider Own29.56%Shs Outstand50.90MPerf Week5.26%
Market Cap488.63MForward P/E48.00EPS next Y0.20Insider Trans-1.39%Shs Float38.90MPerf Month1.16%
Enterprise Value398.63MPEG-EPS next Q0.11Inst Own-Short Float10.99%Perf Quarter26.98%
Income26.00MP/S2.12EPS this Y-26.92%Inst Trans-Short Ratio13.23Perf Half Y56.10%
Sales231.00MP/B3.52EPS next Y-47.37%ROA13.86%Short Interest4.27MPerf YTD61.34%
Book/sh2.73P/C5.20EPS next 5Y-ROE20.85%52W High9.74 -1.44%Perf Year121.20%
Cash/sh1.85P/FCF11.28EPS past 3/5Y210.89% -ROIC18.20%52W Low4.37 119.68%Perf 3Y185.71%
Dividend Est.-EV/EBITDA8.30Sales past 3/5Y0.00% 0.27%Gross Margin74.83%Volatility2.63% 3.74%Perf 5Y34.45%
Dividend TTM-EV/Sales1.73EPS Y/Y TTM-16.13%Oper. Margin13.16%ATR (14)0.35Perf 10Y-83.73%
Dividend Ex-Date-Quick Ratio2.64Sales Y/Y TTM0.43%Profit Margin11.55%RSI (14)61.40Recom2.80
Dividend Gr. 3/5Y-Current Ratio2.91EPS Q/Q26.67%SMA203.29%Beta1.21Target Price-
Payout0.00%Debt/Eq0.22Sales Q/Q9.62%SMA509.84%Rel Volume0.96Prev Close9.52
Employees179LT Debt/Eq0.04EarningsNov 05SMA20032.26%Avg Volume339.62KPrice9.60
IPO DateApr 24, 2012Option/ShortYes / YesEPS/Sales Surpr.375.00% 6.60%Net Debt/EBITDA-0.67Volume327,061Change0.84%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-28-21UpgradeCitigroupNeutral → Buy
Oct-08-19DowngradeGoldman SachsNeutral → Sell
May-10-19DowngradeCitiBuy → Neutral
May-10-19DowngradeCitigroupBuy → Neutral
May-10-19DowngradeCantor FitzgeraldOverweight → Neutral
Jan-03-19DowngradeGuggenheimBuy → Neutral
Nov-19-18UpgradeGoldman SachsSell → Neutral
Nov-02-18DowngradeBarclaysEqual Weight → Underweight
Apr-12-18DowngradeBarclaysOverweight → Equal Weight
Jan-24-18DowngradeCowen & Co.Outperform → Market Perform
Latest News· Times ET
Sep-18-26
Sep-18-2607:51AM
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Beginszacks.com
Sep-17-26
Sep-17-2612:07PM
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancerbusinesswire.com
Sep-09-26
Sep-09-2612:11PM
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conferencebusinesswire.com
Sep-08-26
Sep-08-2607:07AM
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchiseseekingalpha.com
Sep-03-26
Sep-03-2601:00PM
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Sep-02-26
Sep-02-2612:24AM
3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.defenseworld.net
Aug-12-26
Aug-12-2606:41AM
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?zacks.com
Aug-10-26
Aug-10-2603:30PM
Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
Aug-07-26
Aug-07-2608:16AM
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raisedzacks.com
07:14AM
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-06-26
Aug-06-2611:05PM
Puma Biotechnology Q2 Earnings Call Highlightsmarketbeat.com
04:13PM
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimateszacks.com
12:09PM
Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M EstimateBenzinga
12:05PM
Puma Biotechnology Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Aug-05-26
Aug-05-2601:00PM
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Company

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue231228230——————
Cost of Goods Sold Incl. D&A575864——————
Gross Profit172170166——————
Selling, General and Administrative Excl. Other717180——————
Research and Development726255——————
Other Operating Expense
-100——————
Operating Income313731——————
Interest Expense3712——————
Unusual Expense
—————————
Non-Operating Income (Expense)456——————
Net Income Before Taxes313624——————
Income Taxes45-6——————
Consolidated Net Income263130——————
Net Income From Continuing Operations263130——————
Net Income263130——————
EPS (Recurring)0.540.620.62——————
EPS (Basic, Before Extraordinaries)0.540.620.62——————
EPS (Diluted)0.520.610.62——————
EBITDA485348——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio18.469.754.92——————
Price To Sales Ratio2.121.300.65——————
Gross Margin74.4674.5672.17——————
Operating Margin13.4216.2313.48——————
Net Margin11.2613.6013.04——————
Shares Outstanding515049——————
Market Capitalization490298149——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$10.68$8.53$6.38$4.23$2.08● Close Price0.00K153.12K306.25K459.37K612.49KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cesano AlessandraDirectorSep 14 '26Sale9.1262,150566,99456,700Sep 16
Cesano AlessandraDirectorSep 14 '26Option Exercise2.9350,000146,500118,850Sep 16
WILSON TROY EDWARDDirectorSep 14 '26Sale9.105,00045,50054,750Sep 16
HUNT DOUGLAS MSee RemarksJul 06 '26Sale8.268,46069,905196,841Jul 08
AUERBACH ALAN HPresident and CEOJul 06 '26Sale8.2644,058364,0517,261,671Jul 08
NOUGUES MAXIMO FChief Financial OfficerJul 06 '26Sale8.269,38677,557230,637Jul 08
Dorval AllisonDirectorJun 12 '26Sale7.2011,61083,57990,780Jun 15
MOYES JAY MDirectorJun 12 '26Sale7.2222,000158,79658,322Jun 15
Senderowicz AdrianDirectorJun 12 '26Sale7.2027,000194,31127,000Jun 15
WILSON TROY EDWARDDirectorJun 12 '26Sale7.2010,80077,74859,750Jun 15
Stuglik Brian MDirectorJun 12 '26Sale7.208,10058,311113,858Jun 15
AUERBACH ALAN HPresident and CEOJan 07 '26Sale5.8818,012105,8937,145,951Jan 08
HUNT DOUGLAS MSee RemarksJan 07 '26Sale5.885,01429,477155,907Jan 08
NOUGUES MAXIMO FChief Financial OfficerJan 07 '26Sale5.886,40537,655193,284Jan 08
NOUGUES MAXIMO FChief Financial OfficerJan 06 '26Sale5.844,54026,532199,689Jan 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.